Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Deferred revenue by Year
Deferred revenue — Total customer deposits & Advance Purchase Agreements (APAs) ($M) ($M)
Moderna Deferred revenue: $252M in FY2025, up 19.4% from a year earlier.
Latest, FY2025
252
Period ended Dec 31, 2025
Change on a year earlier
+19.4%
211 in FY2024
History
8 years
Since FY2018
Sources
8
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-Q (filed 2026-07-31) ↗
Reported in Form 10-Q / 10-K Note 2 (Contract Liabilities & Deferred Revenue).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Deferred revenue — Total customer deposits & Advance Purchase Agreements (APAs) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 252 | +19.4% | Form 10-Q (filed 2026-07-31) ↗ |
| FY2024 | Dec 31, 2024 | 211 | -67.6% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 651 | -76.0% | Form 10-K (filed 2025-02-21) ↗ |
| FY2022 | Dec 31, 2022 | 2,711 | -60.5% | Form 10-K (filed 2024-02-23) ↗ |
| FY2021 | Dec 31, 2021 | 6,868 | +69.8% | Form 10-K (filed 2023-02-24) ↗ |
| FY2020 | Dec 31, 2020 | 4,044 | +1,899.0% | Form 10-K (filed 2022-02-25) ↗ |
| FY2019 | Dec 31, 2019 | 202 | -16.0% | Form 10-K (filed 2021-02-26) ↗ |
| FY2018 | Dec 31, 2018 | 241 | – | Form 10-K (filed 2020-02-27) ↗ |
Breakdown
What makes up deferred revenue
- Deferred revenue — Current ($M)99 · FY2025
- Deferred revenue — Non-current ($M)153 · FY2025
- Deferred revenue — Product sales (sovereign APAs & customer deposits) ($M)107 · FY2025
- Deferred revenue — Stand-ready manufacturing, collaborations & grants ($M)145 · FY2025
- Deferred revenue — Collaboration arrangements (legacy disaggregation) ($M)6 · FY2024
- Deferred revenue — Government grants (legacy disaggregation) ($M)9 · FY2024
- Revenue recognized from beginning-of-year deferred revenue balance ($M)320 · FY2025
Cite this data
StockData. (2026). Moderna Deferred revenue ($M), annual FY2018–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/def-rev-total
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.